Return to Listing

22 result(s) for Phase I Clinical Trials

PI Name Protocol # Title
Richard Maziarz IRB00009375 A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT
Matthew Taylor IRB00009902 A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Matthew Taylor IRB00010177 A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Matthew Taylor IRB00011638 A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma
Matthew Taylor IRB00011688 A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients with Solid Tumors
Matthew Taylor IRB00011804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Matthew Taylor IRB00012008 CPDR001X2101: Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients with Advanced Malignancies
Michael Heinrich IRB00012061 A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors
Matthew Taylor STUDY00015206 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Emma Scott STUDY00015214 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Matthew Taylor STUDY00015678 A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers
Matthew Taylor STUDY00015716 A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Matthew Taylor STUDY00015752 A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Matthew Taylor STUDY00015911 A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors
Matthew Taylor STUDY00015941 A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer and Melanoma
Matthew Taylor STUDY00016017 An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Alison Skalet STUDY00016162 A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation or Brachytherapy
Matthew Taylor STUDY00016198 A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
Joshi Alumkal STUDY00016294 Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-002)
Joshi Alumkal STUDY00016446 A Safety and Pharmacokinetics Study of Niraparib plus Apalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (protocol 64091742PCR1001)
Matthew Taylor STUDY00016676 A Phase 1 study of the highly-selective RET inhibitor, BLU-667, in patients with thyroid cancer, non-small cell lung cancer (NSCLC) and other advanced solid tumors
Matthew Taylor STUDY00016804 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Malignancies
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080